1-6 of 6
tirzepatide
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program

Philip Zeitler, Rodolfo J. Galindo, Melanie J. Davies, Brandon K. Bergman, Vivian T. Thieu, Claudia Nicolay, Sheryl Allen, Robert J. Heine, Clare J. Lee
Journal: Diabetes Care
Diabetes Care 2024;47(6):1056–1064
https://doi.org/10.2337/dc23-2356
Published: 19 April 2024
View article titled, Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
Open the PDF for Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program in another window
Journal Articles

Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4

Maciej T. Małecki, Rachel L. Batterham, Naveed Sattar, Joshua A. Levine, Ángel Rodríguez, Brandon K. Bergman, Hui Wang, Gabriela Ghimpeteanu, Clare J. Lee
Journal: Diabetes Care
Diabetes Care 2023;46(12):2292–2299
https://doi.org/10.2337/dc23-1135
Published: 12 October 2023
View article titled, Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4
Open the PDF for Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4 in another window
Journal Articles

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

Julio Rosenstock, Luis Vázquez, Stefano Del Prato, Denise Reis Franco, Govinda Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K. Bergman, Angel Rodríguez
Journal: Diabetes Care
Diabetes Care 2023;46(11):1986–1992
https://doi.org/10.2337/dc23-0872
Published: 06 September 2023
View article titled, Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Open the PDF for Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials in another window
Journal Articles

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis

Hiddo J.L. Heerspink, Naveed Sattar, Imre Pavo, Axel Haupt, Kevin L. Duffin, Zhengyu Yang, Russell J. Wiese, Jonathan M. Wilson, Andrea Hemmingway, David Z.I. Cherney, Katherine R. Tuttle
Journal: Diabetes Care
Diabetes Care 2023;46(8):1501–1506
https://doi.org/10.2337/dc23-0261
Published: 02 June 2023
View article titled, Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
Open the PDF for Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis in another window
Journal Articles

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Tim Heise, J. Hans DeVries, Shweta Urva, Jing Li, Edward J. Pratt, Melissa K. Thomas, Kieren J. Mather, Chrisanthi A. Karanikas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Journal: Diabetes Care
Diabetes Care 2023;46(5):998–1004
https://doi.org/10.2337/dc22-1710
Published: 01 March 2023
View article titled, Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Open the PDF for Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes in another window
Journal Articles

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman, Arun J. Sanyal, Rohit Loomba, Jonathan M. Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A. Karanikas, Kevin L. Duffin, Deborah A. Robins, Axel Haupt
Journal: Diabetes Care
Diabetes Care 2020;43(6):1352–1355
https://doi.org/10.2337/dc19-1892
Published: 14 April 2020
View article titled, Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Open the PDF for Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in another window